Scott B Halstead

Summary

Country: USA

Publications

  1. Halstead S, Marchette N. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. Am J Trop Med Hyg. 2003;69:5-11 pubmed
    ..Candidate human vaccines have been prepared from five of the studied strains: DEN-1 (16007) at PDK 13, DEN-2 (16681 and S-16803) at PDK 50 or above, and DEN-4 (1036 and 341750) at PDK 48 and 20, respectively. ..
  2. Halstead S, Thomas S. Japanese encephalitis: new options for active immunization. Clin Infect Dis. 2010;50:1155-64 pubmed publisher
    ..JE is a vaccine-preventable disease with numerous options now available for active immunization. Aggressive and responsible vaccination programs should greatly diminish the burden of disease. ..
  3. Halstead S. Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge. Am J Trop Med Hyg. 2016;95:741-745 pubmed
    ..To achieve a safe and protective dengue vaccine, careful studies of monotypic CYD vaccines in humans should precede field trials of tetravalent formulations. ..
  4. Halstead S, Heinz F, Barrett A, Roehrig J. Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria. Vaccine. 2005;23:849-56 pubmed
    ..Achievement of this aim will require a better understanding of the basic mechanisms by which dengue viruses recognize, attach, enter and infect relevant human cells and how antibodies protect against dengue infections. ..
  5. Halstead S, Thomas S. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev Vaccines. 2011;10:355-64 pubmed publisher
    ..A broad portfolio of safe and effective Japanese encephalitis vaccines has become available to meet the needs of at-risk populations; when appropriately delivered, these new vaccines should greatly diminish the burden of disease. ..
  6. Halstead S. Dengue vaccine development: a 75% solution?. Lancet. 2012;380:1535-6 pubmed publisher
  7. Aye K, Charngkaew K, Win N, Wai K, Moe K, Punyadee N, et al. Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar. Hum Pathol. 2014;45:1221-33 pubmed publisher
    ..The latter findings had previously been reported but overlooked as a diagnostic feature. ..
  8. Halstead S, Aguiar M. Dengue vaccines: Are they safe for travelers?. Travel Med Infect Dis. 2016;14:378-83 pubmed publisher
    ..The NIAID vaccine is promising as a travel vaccine as a single dose fully protected susceptible adults against live dengue 2 virus challenge. The protective efficacy and safety of the Takeda vaccine remain to be demonstrated. ..
  9. Halstead S. Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue. Lancet Infect Dis. 2017;17:e378-e382 pubmed publisher
    ..T-cell immunity might be an essential component of safe, efficacious, and durable Zika virus vaccines. ..
  10. Halstead S, Russell P. Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine. 2016;34:1643-7 pubmed publisher
    ..The implications of the observed mixture of DENV protection and enhanced disease in CYD vaccinees are discussed. ..

Locale

Detail Information

Publications11

  1. Halstead S, Marchette N. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. Am J Trop Med Hyg. 2003;69:5-11 pubmed
    ..Candidate human vaccines have been prepared from five of the studied strains: DEN-1 (16007) at PDK 13, DEN-2 (16681 and S-16803) at PDK 50 or above, and DEN-4 (1036 and 341750) at PDK 48 and 20, respectively. ..
  2. Halstead S, Thomas S. Japanese encephalitis: new options for active immunization. Clin Infect Dis. 2010;50:1155-64 pubmed publisher
    ..JE is a vaccine-preventable disease with numerous options now available for active immunization. Aggressive and responsible vaccination programs should greatly diminish the burden of disease. ..
  3. Halstead S. Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge. Am J Trop Med Hyg. 2016;95:741-745 pubmed
    ..To achieve a safe and protective dengue vaccine, careful studies of monotypic CYD vaccines in humans should precede field trials of tetravalent formulations. ..
  4. Halstead S, Heinz F, Barrett A, Roehrig J. Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria. Vaccine. 2005;23:849-56 pubmed
    ..Achievement of this aim will require a better understanding of the basic mechanisms by which dengue viruses recognize, attach, enter and infect relevant human cells and how antibodies protect against dengue infections. ..
  5. Halstead S, Thomas S. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev Vaccines. 2011;10:355-64 pubmed publisher
    ..A broad portfolio of safe and effective Japanese encephalitis vaccines has become available to meet the needs of at-risk populations; when appropriately delivered, these new vaccines should greatly diminish the burden of disease. ..
  6. Halstead S. Dengue vaccine development: a 75% solution?. Lancet. 2012;380:1535-6 pubmed publisher
  7. Aye K, Charngkaew K, Win N, Wai K, Moe K, Punyadee N, et al. Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar. Hum Pathol. 2014;45:1221-33 pubmed publisher
    ..The latter findings had previously been reported but overlooked as a diagnostic feature. ..
  8. Halstead S, Aguiar M. Dengue vaccines: Are they safe for travelers?. Travel Med Infect Dis. 2016;14:378-83 pubmed publisher
    ..The NIAID vaccine is promising as a travel vaccine as a single dose fully protected susceptible adults against live dengue 2 virus challenge. The protective efficacy and safety of the Takeda vaccine remain to be demonstrated. ..
  9. Halstead S. Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue. Lancet Infect Dis. 2017;17:e378-e382 pubmed publisher
    ..T-cell immunity might be an essential component of safe, efficacious, and durable Zika virus vaccines. ..
  10. Halstead S, Russell P. Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine. 2016;34:1643-7 pubmed publisher
    ..The implications of the observed mixture of DENV protection and enhanced disease in CYD vaccinees are discussed. ..
  11. Halstead S. Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age. Vaccine. 2017;35:6355-6358 pubmed publisher
    ..As hospitalizations continue to occur in all age groups Dengvaxia consumers should be warned that sensitized vaccinated seronegatives will experience enhanced dengue disease into the forseeable future...